UBS Boosts Boston Scientific Price Target to $140 After Strong Q3 Earnings
ByAinvest
Thursday, Nov 13, 2025 11:27 pm ET1min read
BSX--
UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) shares and increased its price target to $140 from $135 after the company's strong Q3 earnings. Boston Scientific reported 21.4% YoY revenue growth and organic sales and earnings per share growth that surpassed UBS and consensus expectations. The company also increased its full-year 2025 outlook, anticipating 20% growth and adjusted EPS of $3.02-$3.04.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet